Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/the-current-use-of-interferons-interleukin-2-and-tumor-necrosis-factor-yME5XSLxaN
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Karger
- Copyright
- © 1991 S. Karger AG, Basel
- ISSN
- 0042-1138
- eISSN
- 1423-0399
- DOI
- 10.1159/000282226
- Publisher site
- See Article on Publisher Site
Abstract
Cytokines such as interferons, interleukin-2 and tumor necrosis factor have been widely tested in the treatment of advanced renal cell cancer. However, the rates of objective remissions (PR and CR) are disappointing and rarely exceed 20% overall. Until now, a definitive cure of a patient with renal cell cancer treated with cytokines has not been reported in the literature. The combination of interferon-α and interleukin-2 in low-dose regimens seems to offer the best achievable results with the lowest morbidity of the patients in renal cell cancer. Since optimal treatment regimens are still not defined, treatment with these substances should only be carried out in prospective trials.
Journal
Urologia Internationalis – Karger
Published: Jan 1, 1991
Keywords: Renal cell cancer; Interferon; Interleukin-2; Tumor necrosis factor